PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) has been assigned an average rating of “Hold” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company.

PBSFF has been the topic of a number of research reports. Citigroup Inc. reiterated a “neutral” rating on shares of PROSIEBENSAT1 MED. in a report on Tuesday, May 9th. BNP Paribas lowered shares of PROSIEBENSAT1 MED. from an “outperform” rating to a “neutral” rating in a report on Friday, July 7th.

Shares of PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) traded down 13.52% on Friday, reaching $33.53. The company had a trading volume of 100 shares. The firm has a market capitalization of $7.67 billion and a price-to-earnings ratio of 15.21. PROSIEBENSAT1 MED. has a 52 week low of $33.53 and a 52 week high of $44.80. The stock’s 50 day moving average is $39.15 and its 200 day moving average is $41.30.

TRADEMARK VIOLATION NOTICE: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/29/prosiebensat1-med-pbsff-given-consensus-rating-of-hold-by-brokerages.html.

PROSIEBENSAT1 MED. Company Profile

Analyst Recommendations for PROSIEBENSAT1 MED. (OTCMKTS:PBSFF)

Receive News & Stock Ratings for PROSIEBENSAT1 MED. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. and related stocks with our FREE daily email newsletter.